|
|
|
|
|
Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer |
| CHEN Bojin1, HU Xingyi1, ZHAO Jingwen1, ZHENG Aihong2 |
| 1. The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310014, China; 2. Department of Oncology Center, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou 310014, China |
|
|
|
|
Abstract The majority of diagnosed cases of gastric cancer are in the middle and late stages, while less than 10% of patients are diagnosed in the early stages in China. The standard treatment strategy for patients with progressive gastric cancer is surgery combined with postoperative adjuvant therapy or preoperative neoadjuvant followed by surgery combined with postoperative adjuvant therapy. Immunotherapy is now recognized as an innovative approach for cancers. It is worth exploring how to best use immunotherapy in neoadjuvant therapy to achieve better clinical benefit. Therefore, this paper reviews the progress of immunotherapy in neoadjuvant therapy for GC. Further studies and the understanding of immune system function by neoadjuvant therapy combined with immunotherapy will help to improve the treatment of gastric cancer.
|
| Keywords
Gastric cancer
Neoadjuvant therapy
Immunotherapy
Tumor microenvironment
|
|
|
| Fund:Department of Education of Zhejiang Province (A.H.Z. Y202044796) |
|
Issue Date: 14 July 2022
|
|
[1] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for
the year 2020: An overview[J]. Int J Cancer, 2021. [Online ahead
of print]
[2] Shitara K, Honma Y, Omuro Y, et al. Efficacy of trastuzumab
emtansine in Japanese patients with previously treated HER2-
positive locally advanced or metastatic gastric or gastroesophageal
junction adenocarcinoma: A subgroup analysis of the GATSBY
study[J]. Asia Pac J Clin Oncol, 2020, 16(1): 5-13.
[3] Li K, Tian H. Development of small-molecule immune checkpoint
inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour
immunotherapy[J]. J Drug Target, 2019, 27(3): 244-256.
[4] Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab
plus ipilimumab or nivolumab monotherapy versus placebo in
patients with resected stage Ⅳ melanoma with no evidence of
disease (IMMUNED): a randomised, double-blind, placebocontrolled,
phase 2 trial[J]. Lancet, 2020, 395(10236): 1558-1568.
[5] Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of
Pembrolizumab Monotherapy in Patients With Previously Treated
Advanced Gastric and Gastroesophageal Junction Cancer: Phase
2 Clinical KEYNOTE-059 Trial[J]. JAMA Oncol, 2018, 4(5):
e180013.
[6] Muro K, Chung HC, Shankaran V, et al. Pembrolizumab
for patients with PD-L1-positive advanced gastric cancer
(KEYNOTE-012): a multicentre, open-label, phase 1b trial[J].
Lancet Oncol, 2016, 17(6): 717-726.
[7] Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with
advanced gastric or gastro-oesophageal junction cancer refractory
to, or intolerant of, at least two previous chemotherapy regimens
(ONO-4538-12, ATTRACTION-2): a randomised, double-blind,
placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111):
2461-2471.
[8] Kawazoe A, Shitara K, Boku N, et al. Current status of
immunotherapy for advanced gastric cancer[J]. Jpn J Clin Oncol,
2021, 51(1): 20-27.
[9] Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 Pathway: Signaling,
Cancer, and Beyond[J]. Adv Exp Med Biol, 2020, 1248: 33-59.
[10] Shitara K, ?zgüro?lu M, Bang YJ, et al. Pembrolizumab versus
paclitaxel for previously treated, advanced gastric or gastrooesophageal
junction cancer (KEYNOTE-061): a randomised,
open-label, controlled, phase 3 trial[J]. Lancet, 2018, 392(10142):
123-133.
[11] Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety
of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs
Chemotherapy Alone for Patients With First-line, Advanced
Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized
Clinical Trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580.
[12] Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab
in combination with S-1/capecitabine plus oxaliplatin in patients
with previously untreated, unresectable, advanced, or recurrent
gastric/gastroesophageal junction cancer: interim results of a
randomized, phase Ⅱ trial (ATTRACTION-4) [J]. Ann Oncol,
2019, 30(2): 250-258.
[13] Cohen R, Pudlarz T, Garcia-Larnicol ML, et al. Localized MSI/
dMMR gastric cancer patients, perioperative immunotherapy
instead of chemotherapy: The GERCOR NEONIPIGA phase Ⅱ
study is opened to recruitment[J]. Bull Cancer, 2020, 107(4):
438-446.
[14] Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy
compared with surgery alone for resectable gastroesophageal
adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ
trial[J]. J Clin Oncol, 2011, 29(13): 1715-1721.
[15] Cunningham D, Allum WH, Stenning SP, et al. Perioperative
c h emo t h e r a p y v e r s u s s u rg e r y a l o n e f o r r e s e c t a b l e
gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20.
[16] Al-Batran SE, Homann N, Pauligk C, et al. Perioperative
chemotherapy with fluorouracil plus leucovorin, oxaliplatin,
and docetaxel versus fluorouracil or capecitabine plus cisplatin
and epirubicin for locally advanced, resectable gastric or gastrooesophageal
junction adenocarcinoma (FLOT4): a randomised,
phase 2/3 trial[J]. Lancet, 2019, 393(10184): 1948-1957.
[17] Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy
compared with surgery alone for resectable gastroesophageal
adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol, 2011, 29(13): 1715-1721.
[18] Cunningham D, Allum WH, Stenning SP, et al. Perioperative
chemotherapy versus surgery alone for resectable gastroesophageal
cancer[J]. New Engl J Med, 2006, 355(1): 11-20.
[19] Al-Batran SE, Homann N, Pauligk C, et al. Perioperative
chemotherapy with fluorouracil plus leucovorin, oxaliplatin,
and docetaxel versus fluorouracil or capecitabine plus cisplatin
and epirubicin for locally advanced, resectable gastric or gastrooesophageal
junction adenocarcinoma (FLOT4): a randomised,
phase 2/3 trial[J]. Lancet, 2019, 393(10184): 1948-1957.
[20] Li X, Huang Q, Lei Y, et al. Locally advanced gastroesophageal
junction cancer with pathological complete response to
neoadjuvant therapy: a case report and literature review[J]. Ann
Transl Med, 2021, 9(6): 513.
[21] Yu Y, Ma X, Zhang Y, et al. Changes in Expression of Multiple
Checkpoint Molecules and Infiltration of Tumor Immune Cells
after Neoadjuvant Chemotherapy in Gastric Cancer[J]. J Cancer,
2019, 10(12): 2754-2763.
[22] Smyth E, Kn?dler M, Giraut A, et al. VESTIGE: Adjuvant
Immunotherapy in Patients With Resected Esophageal,
Gastroesophageal Junction and Gastric Cancer Following
Preoperative Chemotherapy With High Risk for Recurrence (N+
and/or R1): An Open Label Randomized Controlled Phase-2-
Study[J]. Front Oncol, 2019, 9: 1320.
[23] Petrillo A, Pompella L, Tirino G, et al. Perioperative Treatment
in Resectable Gastric Cancer: Current Perspectives and Future
Directions[J]. Cancers (Basel), 2019, 11(3): 399.
[24] Tian Y, Wang J, Qiao X, et al. Long-Term Efficacy of Neoadjuvant
Concurrent Chemoradiotherapy for Potentially Resectable
Advanced Siewert TypeⅡ and ⅢAdenocarcinomas of the
Esophagogastric Junction[J]. Front Oncol, 2021, 11: 756440.
[25] Mole RH. Whole body irradiation; radiobiology or medicine?[J].
Br J Radiol, 1953, 26(305): 234-241.
[26] Sato H, Okonogi N, Nakano T. Rationale of combination of
anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer
treatment[J]. Int J Clin Oncol, 2020, 25(5): 801-809.
[27] Merhi M, Raza A, Inchakalody VP, et al. Persistent anti-NY-ESO-
1-specific T cells and expression of differential biomarkers in a
patient with metastatic gastric cancer benefiting from combined
radioimmunotherapy treatment: a case report[J]. J Immunother
Cancer, 2020, 8(2): e001278.
[28] Wei J, Lu X, Liu Q, et al. Case Report: Neoadjuvant PD-1
Blockade Plus Concurrent Chemoradiotherapy in Unresectable
Locally Advanced Gastric Cancer Patients[J]. Front Oncol, 2020,
10: 554040.
[29] Chung HC, Bang YJ, S Fuchs C, et al. First-line pembrolizumab/
placebo plus trastuzumab and chemotherapy in HER2-positive
advanced gastric cancer: KEYNOTE-811[J]. Future Oncol, 2021,
17(5): 491-501.
[30] Herbst RS, Arkenau HT, Santana-Davila R, et al. Ramucirumab
plus pembrolizumab in patients with previously treated advanced
non-small-cell lung cancer, gastro-oesophageal cancer, or
urothelial carcinomas (JVDF): a multicohort, non-randomised,
open-label, phase 1a/b trial[J]. Lancet Oncol, 2019, 20(8):
1109-1123.
[31]Janjigian YY, Maron SB, Chatila WK, et al. First-line
pembrolizumab and trastuzumab in HER2-positive oesophageal,
gastric, or gastro-oesophageal junction cancer: an open-label,
single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(6): 821-831.
[32] Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study:
Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab
in Patients With Metastatic Esophagogastric Cancer[J]. J Clin
Oncol, 2018, 36(28): 2836-2844.
[33] Bang YJ, Van Cutsem E, Fuchs CS, et al. KEYNOTE-585:
Phase Ⅲ study of perioperative chemotherapy with or without
pembrolizumab for gastric cancer[J]. Future Oncol, 2019, 15(9):
943-952.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
